News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Acucela Inc. Appoints Former Bristol-Myers Squibb Company and F. Hoffmann-La Roche Ltd. Executive, Jaisim Shah, to the Company’s Board of Directors
August 3, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
SEATTLE--(BUSINESS WIRE)--Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, today announced that it has appointed Mr. Jaisim Shah to the Company’s Board of Directors.
Twitter
LinkedIn
Facebook
Email
Print
People
Bristol Myers Squibb Company
MORE ON THIS TOPIC
Mergers & acquisitions
Deal-hungry Lilly strikes up to $2.9B immuno play for Merida
August 31, 2026
·
2 min read
·
Tristan Manalac
cardiovascular disease
‘Worse than expected’ Wainua data muddies water for TTR silencers
August 28, 2026
·
2 min read
·
Gabrielle Masson
Bankruptcy
BioXcel files for bankruptcy, will sell assets to Teva for up to $125M
August 28, 2026
·
1 min read
·
Michael Gibney
Antibody-drug conjugate (ADC)
Genentech strikes second Asia deal in a week, betting up to $1B in oncology ADC alliance with DualityBio
August 28, 2026
·
1 min read
·
Tristan Manalac